ea0026p81 | Endocrine tumours and neoplasia | ECE2011
Mpanaka I
, Antoniou S
, Kanakis G
, Zilos A
, Rousaki P
, Schini M
, Kampanellou C
, Kaltsas G
Purpose: The efficacy and safety of RAD, an mTOR inhibitor, in patients with well differentiated metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).Material and methods: We studied seven male patients (mean age 55 years, range 3675) with well differentiated non functioning stage IV GEP-NETs (five pancreatic, one hindgut carcinoid, and one NET of unknown primary). All received RAD 10 mg/day in combination with long acting octerotide 3...